Table 4 Immunization schedules of U.S. FDA-licensed higher-valent combination vaccines
Vaccine | Trade name (year licensed) | Age range | Routinely recommended ages |
|---|---|---|---|
DTaP-IPV | Kinrix (2008) | 4–6 years | 5th dose of DTaP, and 4th dose of IPV between 4 and 6 years of age |
DTaP-IPV | Quadracel (2015) | 4–6 years | 5th dose of DTaP, and 4th or 5th dose of IPV between 4 and 6 years of age |
DTaP-IPV-Hib | Pentacel (2008) | 6 weeks–4 years | 4-dose series at 2, 4, 6, and 15–18 months of age |
DTaP-HepB-IPV | Pediarix (2002) | 6 weeks–6 years | 3-dose series at 2, 4, and 6 months of age |
DTaP-IPV-Hib-HepB | Vaxelis (2018) | 6 weeks–4 years | 3-dose series at 2, 4, and 6 months of age |